RNAscope fluorescent in situ hybridization (n=3), western blot (n=6), and immunohistochemistry (n=4). NMDAR levels and function were measured by radioligand binding (n=6) and slice electrophysiology (n=21-24 cells). Changes in gene expression were measured by RNAseq of total RNA from male cortex (n=4) that was analyzed with tuxedo protocol on the Galaxy. org online platform. Behaviours were assessed with digital activity monitors (n=40), sociability test (n=20), puzzle box test (n=20), and pre-pulse inhibition of acoustic startle test (n=20). Results: Insertional mutation of Grin1 caused a knockdown of Grin1 mRNA and GluN1 protein that was 10% of wildtype levels, and Cremediated reversal of the mutation led to a substantial increase in Grin1 mRNA and GluN1 protein that was 50% of wildtype levels. Despite the incomplete recovery of protein, the levels of functional NMDAR at the synapse returned to 100% of wildtype levels in the cortex. Cortical behaviours were either substantially or completely normalized in mice with an adult rescue of NMDARs. RNAseq of the cortex indicated that astrocytic transcripts including Gfap, Acan, and Aqp1 were among those with the largest fold-change in both knockdown and rescue animals. Conclusions: While NMDARs play an important role in the developing nervous system, many of the cognitive impairments caused by NMDAR hypofunction can be reversed by interventions that occur in adulthood. Our study of the molecular changes that occur in the process of recovery highlight the role that astrocytes play. Background: Synaptic phospholipids were shown to regulate cortical excitation/inhibition (E/I)-balance and to control sensory information processing in mice and man. However, altered synaptic LPA-signaling was suggested to be associated with psychiatric disorders.
SYNAPTIC LIPID SIGNALING AT CENTRAL SYNAPSES: ROLE IN PSYCHIATRIC DISORDERS
Background: Synaptic phospholipids were shown to regulate cortical excitation/inhibition (E/I)-balance and to control sensory information processing in mice and man. However, altered synaptic LPA-signaling was suggested to be associated with psychiatric disorders.
Methods:
In order to analyze the role of synaptic lipid signaling in psychiatric disorders, we performed electron microscopy, cell culture experiments, mass spectrometry and electrophysiological experiments on transgenic mouse lines, where different elements of cortical synaptic lipid signaling were deleted. These data were corroborated by in-vivo electrophysiological measurements in freely moving mice and by behavioral experiments. Results: Our data show that the LPA-synthesizing enzyme autotaxin (ATX) is expressed in the astrocytic compartment of excitatory synapses and modulates glutamatergic transmission. In astrocytes, ATX is sorted towards fine astrocytic processes and transported to excitatory but not inhibitory synapses. This ATX-sorting as well as the enzymatic activity of astrocytesderived ATX are dynamically regulated by neuronal activity via astrocytic glutamate receptors. Pharmacological and genetic ATX-inhibition both rescued schizophrenia-related hyperexcitability syndromes caused by altered bioactive lipid signaling in two genetic mouse models for psychiatric disorders. Interestingly, ATX-inhibition did not affect naive animals. However, since our data suggested that pharmacological ATX-inhibition is a general method to reverse cortical excitability, we applied ATX-inhibition in a ketamine model of schizophrenia and rescued thereby the electrophysiological and behavioral schizophrenia-like phenotype. Conclusions: We conclude that astrocytic ATX is a novel modulator of glutamatergic transmission and that targeting ATX might be a versatile strategy for a novel drug therapy to treat cortical hyperexcitability in psychiatric disorders. Background: Glutamatergic abnormalities are commonly observed in schizophrenia (SZ) and are hypothesized to play an important role in cognitive dysfunction. While the contribution of postsynaptic glutamate receptors to SZ psychopathology has been extensively examined, less is known about the role played by enzymes involved in glutamate metabolism and homeostasis. We examined mice with a brain-wide deficit in the glutamate metabolizing enzyme glutamate dehydrogenase (GDH), encoded by Glud1, which leads to glutamate excess due to reduced glutamate metabolism in astrocytes.
We investigated astrocytic and neuronal abnormalities in mice with a CNS-specific mutation in Glud1. We asked whether CNS-Glud1 deficient mice would display behavioral abnormalities in a battery of tests that assess different aspects of schizophrenia-like psychopathology. We further asked whether an environmental manipulation, i.e., stress exposure, would exacerbate the behavioral abnormalities and astrocytic-neuronal gene expression patterns in heterozygous and homozygous mice.
Results:
We found that mice with a homozygous mutation in CNS-Glud1, with a primarily astrocytic deficit in glutamate metabolism, display enhanced glutamate levels, an elevated excitatory/inhibitory balance in CA1, and abnormally high mRNA expression of neuronal and astrocytic markers of glutamate transmission specifically in dorsal CA1. Homozygous Glud1-deficient mice also showed several behavioral abnormalities, e.g., amphetamine-induced hyperlocomotion, nest building and social preference deficits, and abnormal reversal/extradimensional set shifting in the water T-maze. While heterozygous mice displayed no major behavioral or molecular abnormalities, their exposure to stress led to cognitive dysfunction; this gene x environment interaction may be mediated by disrupted function of the neuron-glia interface.
Conclusions:
Collectively, these studies show that GDH-mediated glutamate metabolism in astrocytes impacts on neuronal glutamate transmission and release. GDH disruption, also demonstrated in post-mortem CA1 of patients with SZ, leads to SZ-like deficits in mice. GDH disruption and exposure to stress may cumulatively disrupt neuronal-astrocytic communication. These findings could lead to better understanding of the glutamate tripartite synapse and its contribution to SZ-like etiology. 
CELL-TYPE SPECIFIC ALTERATIONS IN ADENOSINE-GENERATING PATHWAYS IN SCHIZOPHRENIA
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Background: Adenosine is a potent neuromodulator of glutamate and dopamine neurotransmission and abnormalities of adenosine metabolism are a possible pathophysiological mechanism postulated to underlie the signs and symptoms of schizophrenia. Extracellular adenosine is mainly generated in two ways. ATP is released into the extracellular space and converted to adenosine via a series of enzymatic steps. Alternatively, adenosine is directly released from cells via equilibrative nucleoside transporters (ENTs). Indirect generation of adenosine via conversion of ATP is more typical of glial cells, while direct adenosine release is more typical of neurons, although the enzymes required to generate adenosine and the ENT transporters are found in both cell types. The relative contributions of Downloaded from https://academic.oup.com/schizophreniabulletin/article-abstract/45/Supplement_2/S124/5434653 by guest on 30 April 2019
